News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actavis (ACT) To Present At Morgan Stanley (MST) Global Healthcare Conference 2014


8/27/2014 8:16:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Aug. 26, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brenton Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Morgan Stanley Global Healthcare Conference 2014 in New York, NY.

Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

The presentation will take place on Tuesday, September 9, 2014 at 11:10 AM Eastern Time at the Grand Hyatt New York, 109 East 42nd Street, New York, NY 10017.  To access a live webcast of the presentation, visit Actavis' Investor Relations Web site at http://ir.actavis.com.  The webcast can also be accessed at the following URL:

http://cc.talkpoint.com/morg007/090814a_ac/?entity=46_IDMWBNE

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Actavis

Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. 

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.  The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications.  Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.

 CONTACTS: 

Investors:


Lisa DeFrancesco


(862) 261-7152




Media:


Charlie Mayr


(862) 261-8030




David Belian


(862) 261-8141

SOURCE Actavis plc

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES